Pill Identifier App

Dextrose and Sodium Chloride Injection

Dosage Form: injection, solution

Dextrose and Sodium Chloride
Injection, USP

VisIV ™ Container

Rx only

Dextrose and Sodium Chloride Injection Description

Dextrose and Sodium Chloride Injection, USP solutions are sterile and nonpyrogenic. They are large volume parenteral solutions containing various concentrations and combinations of these drugs in water for injection intended for intravenous administration.

See Table for summary of content and characteristics of these solutions.

The solutions contain no bacteriostat, antimicrobial agent or added buffer and each is intended only as a single-dose injection. When smaller doses are required, the unused portion should be discarded.

Slideshow: HealthQuiz: Basics About Stroke Signs and Symptoms

The solutions are parenteral fluid, nutrient and electrolyte replenishers.

Dextrose, USP is chemically designated D-glucose monohydrate (C6H12O6 • H2O), a hexose sugar freely soluble in water. It has the following structural formula:

Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water.

Water for Injection, USP is chemically designated H20.

The flexible plastic container is fabricated from a clear multilayer polyolefin plastic film. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period.

Dextrose and Sodium Chloride Injection - Clinical Pharmacology

When administered intravenously, these solutions provide a source of water, carbohydrate and electrolytes.

Solutions which provide combinations of hypotonic or isotonic concentrations of dextrose and of sodium chloride are suitable for parenteral maintenance or replacement of water and electrolyte requirements with minimal carbohydrate calories.

Solutions containing carbohydrate in the form of dextrose restore blood glucose levels and provide calories. Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein-sparing action. Dextrose injected parenterally undergoes oxidation to carbon dioxide and water.

Sodium chloride in water dissociates to provide sodium (Na+) and chloride (Cl-) ions. Sodium (Na+) is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Chloride (Cl-) has an integral role in buffering action when oxygen and carbon dioxide exchange occurs in the red blood cells. The distribution and excretion of sodium (Na+) and chloride (Cl-) are largely under the control of the kidney which maintains a balance between intake and output.

Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirements range from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production). Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na+) plays a major role in maintaining physiologic equilibrium.

Indications and Usage for Dextrose and Sodium Chloride Injection

Intravenous solutions containing dextrose and sodium chloride are indicated for parenteral replenishment of fluid, minimal carbohydrate calories, and sodium chloride as required by the clinical condition of the patient.

Contraindications

None known.

Warnings

Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.

Excessive administration of potassium-free solutions may result in significant hypokalemia.

In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention.

The intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.

The risk of dilutional states is inversely proportional to the electrolyte concentrations of administered parenteral solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions.

Precautions

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.

Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions to patients receiving corticosteroids or corticotropin.

Do not administer unless solution is clear and container is undamaged. Discard unused portion.

Pregnancy: Teratogenic effects

Pregnancy Category C. Animal reproduction studies have not been conducted with dextrose or sodium chloride. It is also not known whether dextrose or sodium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dextrose or sodium chloride should be given to a pregnant woman only if clearly needed.

Pediatric Use. The safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations. In neonates or very small infants, the volume of fluid may affect fluid and electrolyte balance.

Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants.

In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage.

Geriatric Use. An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Sodium ions are known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Adverse Reactions

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

Overdosage

In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS.

 

Dextrose and Sodium Chloride Injection Dosage and Administration

The dose is dependent upon the age, weight and clinical condition of the patient.

As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.

Drug Interactions

Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.

INSTRUCTIONS FOR USE

Check for leaks by squeezing container firmly. If leaks are found, discard unit as sterility may be impaired. If supplemental medication is desired, follow directions below before preparing for administration.

To Add Medication

(Use aseptic technique)

1. Remove blue cap from BLU-MED™ sterile medication additive port at bottom of container.

2. With a needle of appropriate length, puncture resealable additive port and inject. Withdraw needle after injecting medication.

3. Mix container contents thoroughly.

4. The additive port may be protected by an appropriate cover.

Preparation for Administration

(Use aseptic technique)

NOTE: See appropriate I.V. administration set Instructions for Use.

1. Close flow control clamp of administration set.

2. Remove cap from sterile administration set port at bottom of container.

3. Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated.

4. Suspend container.

5. Squeeze and release drip chamber to establish proper fluid level in chamber.

6. Open clamp. Eliminate air from remainder of set.

7. Attach set to patient access device.

8. Begin infusion.

WARNING: Do not use flexible container in series connections.

How is Dextrose and Sodium Chloride Injection Supplied

Dextrose and Sodium Chloride Injection, USP are supplied in single-dose flexible plastic containers in various sizes and concentrations as shown in the accompanying Table:

Content and Characteristics

Grams/100 mL

Per 1000 mL

Container size (mL)

NDC No.

Product

Dextrose (hydrous)

Sodium Chloride

Sodium Na+

Chloride Cl-

Caloric Value

Tonicity

Osmolarity mOsmol/L (calc)

pH

250

500

1000

0409–7924–25

5% Dextrose and 0.225% Sodium Chloride Inj., USP

5

0.225

38.5 mEq

38.5 mEq

170

Hypertonic

329

4.3 (3.5 to 6.5)

X



0409–7924–30

5% Dextrose and 0.225% Sodium Chloride Inj., USP

5

0.225

38.5 mEq

38.5 mEq

170

Hypertonic

329

4.3 (3.5 to 6.5)


X


0409–7924–48

5% Dextrose and 0.225% Sodium Chloride Inj., USP

5

0.225

38.5 mEq

38.5 mEq

170

Hypertonic

329

4.3 (3.5 to 6.5)



X

0409–7925–25

5% Dextrose and 0.3% Sodium Chloride Inj., USP

5

0.3

51 mEq

51 mEq

170

Hypertonic

355

4.3 (3.5 to 6.5)

X



0409–7925–30 5% Dextrose and 0.3% Sodium Chloride Inj., USP 5 0.3 51 mEq 51 mEq 170 Hypertonic 355 4.3 (3.5 to 6.5)
X
0409–7925–48 5% Dextrose and 0.3% Sodium Chloride Inj., USP 5 0.3 51 mEq 51 mEq 170 Hypertonic 355 4.3 (3.5 to 6.5)

X

0409–7926–25

5% Dextrose and 0.45% Sodium Chloride Inj., USP

5

0.45

77 mEq

77 mEq

170

Hypertonic

406

4.3 (3.5 to 6.5)

X



0409–7926–30

5% Dextrose and 0.45% Sodium Chloride Inj., USP

5

0.45

77 mEq

77 mEq

170

Hypertonic

406

4.3 (3.5 to 6.5)


X


0409–7926–48

5% Dextrose and 0.45% Sodium Chloride Inj., USP

5

0.45

77 mEq

77 mEq

170

Hypertonic

406

4.3 (3.5 to 6.5)



X

0409–7941–25

5% Dextrose and 0.9% Sodium Chloride Inj., USP

5

0.9

154 mEq

154 mEq

170

Hypertonic

560

4.3 (3.5 to 6.5)

X



0409–7941–30

5% Dextrose and 0.9% Sodium Chloride Inj., USP

5

0.9

154 mEq

154 mEq

170

Hypertonic

560

4.3 (3.5 to 6.5)


X


0409–7941–48

5% Dextrose and 0.9% Sodium Chloride Inj., USP

5

0.9

154 mEq

154 mEq

170

Hypertonic

560

4.3 (3.5 to 6.5)



X

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing.

Revised: July, 2009

Printed in USA                                                        EN - 2181

Hospira, Inc., Lake Forest, IL 60045 USA

IM-1698

 

IM-1699

 

IM-1700

 

IM-1834

 

DEXTROSE AND SODIUM CHLORIDE 
dextrose monohydrate and sodium chloride injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0409-7924
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
DEXTROSE MONOHYDRATE (ANHYDROUS DEXTROSE) DEXTROSE MONOHYDRATE 5 g  in 100 mL
SODIUM CHLORIDE (SODIUM CATION and CHLORIDE ION) SODIUM CHLORIDE 0.225 g  in 100 mL
Inactive Ingredients
Ingredient Name Strength
WATER  
Packaging
# Item Code Package Description
1 NDC:0409-7924-25 24 BAG in 1 CASE
1 250 mL in 1 BAG
2 NDC:0409-7924-30 24 BAG in 1 CASE
2 500 mL in 1 BAG
3 NDC:0409-7924-48 12 BAG in 1 CASE
3 1000 mL in 1 BAG
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA017606 08/13/1975
DEXTROSE AND SODIUM CHLORIDE 
dextrose monohydrate and sodium chloride injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0409-7926
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
DEXTROSE MONOHYDRATE (ANHYDROUS DEXTROSE) DEXTROSE MONOHYDRATE 5 g  in 100 mL
SODIUM CHLORIDE (SODIUM CATION and CHLORIDE ION) SODIUM CHLORIDE 0.45 g  in 100 mL
Inactive Ingredients
Ingredient Name Strength
WATER  
Packaging
# Item Code Package Description
1 NDC:0409-7926-25 24 BAG in 1 CASE
1 250 mL in 1 BAG
2 NDC:0409-7926-30 24 BAG in 1 CASE
2 500 mL in 1 BAG
3 NDC:0409-7926-48 12 BAG in 1 CASE
3 1000 mL in 1 BAG
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA017607 08/13/1975
DEXTROSE AND SODIUM CHLORIDE 
dextrose monohydrate and sodium chloride injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0409-7941
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
DEXTROSE MONOHYDRATE (ANHYDROUS DEXTROSE) DEXTROSE MONOHYDRATE 5 g  in 100 mL
SODIUM CHLORIDE (SODIUM CATION and CHLORIDE ION) SODIUM CHLORIDE 0.9 g  in 100 mL
Inactive Ingredients
Ingredient Name Strength
WATER  
Packaging
# Item Code Package Description
1 NDC:0409-7941-25 24 BAG in 1 CASE
1 250 mL in 1 BAG
2 NDC:0409-7941-30 24 BAG in 1 CASE
2 500 mL in 1 BAG
3 NDC:0409-7941-48 12 BAG in 1 CASE
3 1000 mL in 1 BAG
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA017585 01/07/1976
DEXTROSE AND SODIUM CHLORIDE 
dextrose monohydrate and sodium chloride injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0409-7925
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
DEXTROSE MONOHYDRATE (ANHYDROUS DEXTROSE) DEXTROSE MONOHYDRATE 5 g  in 100 mL
SODIUM CHLORIDE (SODIUM CATION and CHLORIDE ION) SODIUM CHLORIDE 0.3 g  in 100 mL
Inactive Ingredients
Ingredient Name Strength
WATER  
Packaging
# Item Code Package Description
1 NDC:0409-7925-25 24 BAG in 1 CASE
1 250 mL in 1 BAG
2 NDC:0409-7925-30 24 BAG in 1 CASE
2 500 mL in 1 BAG
3 NDC:0409-7925-48 12 BAG in 1 CASE
3 1000 mL in 1 BAG
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA017799 04/12/1977
Labeler - Hospira, Inc. (141588017)
Revised: 03/2014
 
Hospira, Inc.

More about dextrose/sodium chloride

Hide
(web2)